GW Phar­ma shares surge on pos­i­tive PhI­II fol­lowup; Il­lu­mi­na leads $18M round for Stil­la's DNA tech

→ GW Phar­ma $GW­PH al­ready won their big FDA ap­proval to sell Epid­i­olex for rare seizure cas­es, set­ting the ground­break­ing cannabi­noid drug on track to what many ex­perts will be­lieve will be­come a block­buster. So their sec­ond round of pos­i­tive Phase III da­ta in Dravet syn­drome can be con­sid­ered ic­ing on the cake. Both dos­es of the drug pro­duced sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tions in con­vul­sive seizures com­pared to a place­bo. The com­pa­ny’s stock surged 4% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER